Mitochondrial Modulator Conjugate for Brain Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Therapeutic delivery to the brain of mitochondrial modulators is challenging due to the need to traverse the blood-brain barrier and localize within brain cell cytoplasm to interact with mitochondria.
Innovation Solution
Compositions comprising a mitochondrial modulator, a blood-brain barrier transcytosis mediator, and a neuronal cell plasma membrane transduction mediator, often tethered together as a single polypeptide, to target defective neuronal mitochondria in neurological disorders like Parkinson's and Alzheimer's.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a mitochondrial modulator is administered systemically, then it can reach the brain, but it cannot effectively traverse the blood-brain barrier and localize to mitochondria
Solution Approach 1:
The delivery system is segmented into three functional modules: a mitochondrial modulator moiety, a blood-brain barrier transcytosis mediator moiety, and a neuronal plasma membrane transduction mediator moiety. These segments are tethered together to form a unified conjugate that sequentially overcomes each barrier (blood-brain barrier, cell membrane, mitochondrial import) through dedicated molecular components, ensuring reliable mitochondrial delivery without requiring complex external delivery systems
Solution Approach 2:
Multiple functional moieties are merged into a single conjugate molecule. The blood-brain barrier transcytosis mediator and neuronal plasma membrane transduction mediator are covalently tethered to the mitochondrial modulator, creating an integrated delivery vehicle that combines barrier-penetration capabilities with mitochondrial targeting and modulation functions in one molecular entity
2Reliability
If the mitochondrial modulator is designed to be highly specific to mitochondria, then it loses the ability to cross the blood-brain barrier and cell membranes
Solution Approach 1:
The conjugate is divided into distinct functional segments where the mitochondrial modulator moiety retains its specific mitochondrial targeting and modulation properties, while separate moieties (blood-brain barrier transcytosis mediator and neuronal plasma membrane transduction mediator) are attached to provide barrier-crossing capabilities. This segmentation allows each component to perform its specialized function without compromising the others
Solution Approach 2:
The blood-brain barrier transcytosis mediator and neuronal plasma membrane transduction mediator act as intermediary components that facilitate the delivery of the mitochondrial modulator across biological barriers. These mediator moieties are temporarily associated with the modulator during delivery, enabling barrier traversal while the modulator's intrinsic mitochondrial specificity is preserved for the final targeting step
Data Source
AI summary
Approaches and compositions for modulation of mitochondria in the context of neurological disorders are disclosed. Through the disclosure herein, pharmaceuticals are delivered to cells within the brain so as to modulate mitochondrial activity, so as to treat or prevent onset of neurological disorders such as Alzheimer's disease or Parkinson's disease. Delivery is mediated through signals such as polypeptide segments that mediate blood brain barrier passage and neuronal cellular uptake of a pharmaceutical comprising a mitochondrial modulator such as a BNIP3 segment, a structural protein or a transcription factor or transcript stabilizer.